利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.033 秒)

    Directed complementation
    1.
    发明授权
    Directed complementation 失效
    导向互补

    公开(公告)号：US07556796B2

    公开(公告)日：2009-07-07

    申请号：US11398171

    申请日：2006-04-05

    申请人： Murray Robinson ,  Ronan O'Hagan ,  Karuppiah Kannan ,  Ti Cai ,  Maria Isabel Chiu ,  Lorena Lerner ,  Jie Lin ,  Yinghui Zhou

    发明人： Murray Robinson ,  Ronan O'Hagan ,  Karuppiah Kannan ,  Ti Cai ,  Maria Isabel Chiu ,  Lorena Lerner ,  Jie Lin ,  Yinghui Zhou

    IPC分类号： A61K49/00 ,  A61K35/12

    CPC分类号： A01K67/0271 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0331 ,  C07K14/82 ,  C12N15/8509 ,  C12N2830/002

    摘要： A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary and sufficient for the tumorigenicity of the tumorigenic mouse cell, and (ii) the inducible promoter is in the uninduced state; and (b) introducing into the cell a recombinant gene of interest that functionally complements the oncogene, thereby restoring tumorigenicity without expression of the inducible recombinant oncogene. Also disclosed is a method of testing a compound for anti-tumor effects. The method includes producing tumorigenic mouse cells the tumorigenicity depends on expression of a recombinant gene of interest, implanting the cells in mice and obtaining tumors from the implanted cells, administering test compounds to the mice, and determining anti-tumor effects, if any, of the compounds.

    摘要翻译： 公开了一种致瘤性小鼠细胞的产生方法取决于感兴趣的重组基因的方法。 该方法包括：（a）提供含有可操作地连接到诱导型启动子的重组癌基因的条件致瘤小鼠细胞，其中（i）重组癌基因的表达对于致瘤性小鼠细胞的致瘤性是必要和足够的，以及（ii） 诱导型启动子处于未诱导状态; 和（b）在细胞中引入功能上补充致癌基因的重组基因，从而恢复致瘤性而不表达可诱导的重组癌基因。 还公开了测试化合物抗肿瘤作用的方法。 该方法包括产生致瘤性小鼠细胞，其致瘤性取决于感兴趣的重组基因的表达，将细胞植入小鼠中并从植入的细胞中获得肿瘤，向小鼠施用测试化合物，并测定抗肿瘤作用（如果有的话） 化合物。

    Directed complementation
    3.
    发明申请
    Directed complementation 审中-公开
    导向互补

    公开(公告)号：US20060222590A1

    公开(公告)日：2006-10-05

    申请号：US11282847

    申请日：2005-11-17

    申请人： Murray Robinson ,  Ronan O'Hagan ,  Karuppiah Kannan ,  Ti Cai

    发明人： Murray Robinson ,  Ronan O'Hagan ,  Karuppiah Kannan ,  Ti Cai

    IPC分类号： A61K49/00 ,  C12N5/06

    CPC分类号： A01K67/0271 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0331 ,  C07K14/82 ,  C12N15/8509 ,  C12N2830/002

    摘要： A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary and sufficient for the tumorigenicity of the tumorigenic mouse cell, and (ii) the inducible promoter is in the uninduced state; and (b) introducing into the cell a recombinant gene of interest that functionally complements the oncogene. Also disclosed is a method of testing a compound for anti-tumor effects. The method includes producing tumorigenic mouse cells the tumorigenicity depends on expression of a recombinant gene of interest, implanting the cells in mice and obtaining tumors from the implanted cells, administering test compounds to the mice, and determining anti-tumor effects, if any, of the compounds.

    摘要翻译： 公开了一种致瘤性小鼠细胞的产生方法取决于感兴趣的重组基因的方法。 该方法包括：（a）提供含有可操作地连接到诱导型启动子的重组癌基因的条件致瘤小鼠细胞，其中（i）重组癌基因的表达对致瘤性小鼠细胞的致瘤性是必要和足够的，和（ii） 诱导型启动子处于未诱导状态; 和（b）向细胞中引入功能上补充致癌基因的重组感兴趣基因。 还公开了测试化合物抗肿瘤作用的方法。 该方法包括产生致瘤性小鼠细胞，其致瘤性取决于感兴趣的重组基因的表达，将小鼠植入细胞并从植入的细胞中获得肿瘤，向小鼠施用测试化合物，并测定抗肿瘤作用（如果有的话） 化合物。

    Directed complementation
    4.
    发明申请
    Directed complementation 审中-公开

    公开(公告)号：US20060222589A1

    公开(公告)日：2006-10-05

    申请号：US11099735

    申请日：2005-04-05

    申请人： Murray Robinson ,  Ronan O'Hagan ,  Karuppiah Kannan ,  Ti Cai

    发明人： Murray Robinson ,  Ronan O'Hagan ,  Karuppiah Kannan ,  Ti Cai

    IPC分类号： A61K49/00 ,  C12N5/06

    CPC分类号： A61K49/0008

    摘要： A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary and sufficient for the tumorigenicity of the tumorigenic mouse cell, and (ii) the inducible promoter is in the uninduced state; and (b) introducing into the cell a recombinant gene of interest that functionally complements the oncogene. Also disclosed is a method of testing a compound for anti-tumor effects. The method includes producing tumorigenic mouse cells the tumorigenicity depends on expression of a recombinant gene of interest, implanting the cells in mice and obtaining tumors from the implanted cells, administering test compounds to the mice, and determining anti-tumor effects, if any, of the compounds.

    Identifying cancers sensitive to treatment with inhibitors of notch signaling
    6.
    发明授权
    Identifying cancers sensitive to treatment with inhibitors of notch signaling 有权
    鉴定对使用缺口信号抑制剂治疗敏感的癌症

    公开(公告)号：US07544476B1

    公开(公告)日：2009-06-09

    申请号：US12360790

    申请日：2009-01-27

    申请人： Ronan O'Hagan ,  H. Heidi Okamura ,  Alisa C. Bell ,  Jeanine Lorusso

    发明人： Ronan O'Hagan ,  H. Heidi Okamura ,  Alisa C. Bell ,  Jeanine Lorusso

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158

    摘要： The disclosure provides a method for identifying cancer tissue sensitive to treatment with an inhibitor of Notch receptor activation. The method comprises determining the level of HeyL gene expression in a sample derived from the cancer tissue, wherein an elevated level of HeyL gene expression alone in the sample indicates sensitivity to the cancer tissue to treatment with an inhibitor of Notch receptor activation.

    摘要翻译： 本公开提供了用于鉴定对用Notch受体激活抑制剂治疗敏感的癌组织的方法。 该方法包括确定衍生自癌组织的样品中HeyL基因表达的水平，其中样品中单独提高的HeyL基因表达水平表示对癌组织的敏感性，以用Notch受体激活抑制剂进行治疗。